Ubidecarenone
Ubidecarenone is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| avalon organics coq10 repair wrinkle defense broad spectrum spf15 | OTC monograph final | 2012-10-31 |
| florafol fe pediatric 0.25 mg/ml multivitamin and fluoride liquid drops | unapproved drug other | 2023-12-22 |
| florafol pediatric 0.25 mg/ml multivitamin and fluoride liquid drops | unapproved drug other | 2023-12-22 |
| mecell rose coenzyme q10 serum mask pack | OTC monograph final | 2014-12-28 |
| zyrexal | unapproved drug other | 2020-02-10 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
316 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infertility | D007246 | HP_0000789 | — | 1 | 2 | — | 2 | 8 | 13 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | 1 | — | 1 | 2 | 7 | 11 |
| Male infertility | D007248 | EFO_0004248 | N46 | — | 1 | — | 1 | 7 | 9 |
| Hypercholesterolemia | D006937 | HP_0003124 | — | — | 1 | — | 3 | 5 | 9 |
| Inflammation | D007249 | MP_0001845 | — | — | 3 | 2 | 2 | 3 | 8 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | 1 | 1 | 5 | 7 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 1 | 3 | 1 | 2 | 1 | 7 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | 1 | — | 1 | 4 | 6 |
| Oxidative stress | D018384 | EFO_1001905 | — | 1 | 2 | 1 | 1 | 2 | 6 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 1 | 1 | 2 | 1 | 5 |
Show 35 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | — | — | 1 | 8 | 2 | — | 11 | 20 |
| Fatigue | D005221 | HP_0012378 | R53.83 | 3 | 4 | 2 | — | 6 | 12 |
| Mitochondrial diseases | D028361 | EFO_0000591 | — | — | 3 | 4 | — | 4 | 10 |
| Healthy volunteers/patients | — | — | — | 3 | 1 | 1 | — | 4 | 9 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 6 | 4 | — | — | 8 |
| Colorectal neoplasms | D015179 | — | — | 2 | 3 | 3 | — | — | 6 |
| Chronic fatigue syndrome | D015673 | EFO_0004540 | G93.31 | — | 2 | 2 | — | 3 | 6 |
| Lymphoma | D008223 | — | C85.9 | — | 5 | 1 | — | — | 6 |
| Ataxia | D001259 | — | R27.0 | 1 | 2 | 2 | — | — | 5 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 1 | 1 | — | 1 | 5 |
Show 69 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sclerosis | D012598 | — | — | 3 | 4 | — | — | — | 5 |
| Keratoconjunctivitis sicca | D007638 | EFO_1000906 | — | — | 1 | — | — | 3 | 4 |
| Dry eye syndromes | D015352 | — | H04.12 | — | 1 | — | — | 3 | 4 |
| Sarcopenia | D055948 | EFO_1000653 | M62.84 | 1 | 1 | — | — | 2 | 4 |
| Retinal diseases | D012164 | HP_0000479 | H35.9 | 1 | 2 | — | — | 1 | 4 |
| Diabetic retinopathy | D003930 | EFO_0003770 | — | 1 | 2 | — | — | 1 | 4 |
| Covid-19 | D000086382 | — | — | — | 1 | — | — | 3 | 4 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | 2 | — | — | — | 3 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 2 | — | — | — | 3 |
| Leukemia | D007938 | — | C95 | — | 3 | — | — | — | 3 |
Show 72 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glaucoma | D005901 | EFO_0000516 | H40 | 1 | — | — | — | 4 | 5 |
| Open-angle glaucoma | D005902 | EFO_0004190 | H40.1 | 1 | — | — | — | 3 | 4 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | — | — | — | 2 | 3 |
| Aging | D000375 | GO_0007568 | R41.81 | 1 | — | — | — | 2 | 3 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | 1 | — | — | — | 1 | 2 |
| Hypoxia | D000860 | HP_0012418 | R09.02 | 2 | — | — | — | — | 2 |
| Oligospermia | D009845 | — | N46.1 | 1 | — | — | — | 1 | 2 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | — | — | — | — | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
| Urinary bladder neoplasms | D001749 | — | C67 | 1 | — | — | — | — | 1 |
Show 19 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Periodontal diseases | D010510 | — | K05.6 | — | — | — | — | 3 | 3 |
| Macular edema | D008269 | — | — | — | — | — | — | 2 | 2 |
| Vomiting | D014839 | HP_0002013 | R11.1 | — | — | — | — | 2 | 2 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 2 | 2 |
| Aneuploidy | D000782 | — | — | — | — | — | — | 2 | 2 |
| Muscular diseases | D009135 | HP_0003198 | G72.9 | — | — | — | — | 2 | 2 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | — | — | 2 | 2 |
| Edema | D004487 | HP_0000969 | R60.9 | — | — | — | — | 1 | 1 |
| Myofascial pain syndromes | D009209 | EFO_1001054 | — | — | — | — | — | 1 | 1 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | — | — | — | 1 | 1 |
Show 60 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ubidecarenone |
| INN | ubidecarenone |
| Description | Coenzyme Q10 is a ubiquinone having a side chain of 10 isoprenoid units. In the naturally occurring isomer, all isoprenyl double bonds are in the E- configuration. It has a role as a human metabolite, a ferroptosis inhibitor and an antioxidant. |
| Classification | Small molecule |
| Drug class | aldosterone antagonists (spironolactone type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COC1=C(OC)C(=O)C(C/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C)=C(C)C1=O |
Identifiers
| PDB | — |
| CAS-ID | 303-98-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL454801 |
| ChEBI ID | 46245 |
| PubChem CID | 5281915 |
| DrugBank | — |
| UNII ID | EJ27X76M46 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 47,036 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
541 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use